Distributed Bio announced an agreement with Pfizer Inc. to license the Distributed Bio SuperHuman Platform for the identification of novel antibodies for use as therapeutic agents. Under the terms of the agreement, Distributed Bio will transfer and license its proprietary SuperHuman 2.0 antibody discovery platform to Pfizer, which will utilize the SuperHuman Antibody Library to perform screening activities against Pfizer-selected targets. Pfizer has also secured access to continued improvements to the SuperHuman Platform. Distributed Bio will receive an undisclosed annual licensing fee and future payments upon achievement of specified preclinical and clinical milestones.